The new omega-3 player is producing algae-based omega-3 eicosapentaenoic acid (EPA).
Aurora Algae Pty. Ltd. (West Perth, Western Australia) has announced several new milestones in its production of algae-based biomass.
On top of Aurora Algae opening a 20-acre demonstration facility in Karratha, Western Australia, the company has also secured an option agreement for more than 1500 acres of land near its demo facility to construct a full-scale commercial manufacturing facility.
Aurora Algae has also received $946,000 AUD in LEEDS grant funding and $750,000 AUD in R&D tax credits from the Australian government in addition to previous LEEDS funding.
These initiatives will enable the company to speed up commercialization of its algae biomass, intended for a variety of applications including vegetarian omega-3 eicosapentaenoic acid (EPA).
Aurora Algae produces algae-based biomass for the nutraceutical, pharmaceutical, aquaculture, and renewable energy markets. The company owns a U.S. processing center in Hayward, California while producing biomass in the “ideal environmental conditions” of Western Australia.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.